GLS and pulmonary arterial hypertension: Therefore, a strategy of repurposing these inhibitors for YAP, GLS1, or miR-130/301, potentially along with a LXR agonist and/or AMPK modulator, may provide a rare opportunity to offer novel “matrix” therapeutics for PAH without the delay of needing to develop new inhibitors de novo.